BACKGROUND: Sac behavior after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) is considered as a surrogate for the risk of late rupture. The purpose of the study is to assess the sac behavior of AAAs after EVAR. METHODS AND RESULTS: Late sac enlargement (LSE) (≥5 mm) and late sac shrinkage (LSS) (≥5 mm) were analyzed in 589 consecutive patients who were registered at 14 national centers in Japan. The proportions of patients who had LSE at 1, 3 and 5 years were 2.6% ± 0.7%, 10.0% ± 1.6% and 19.0% ± 2.9%. The proportions of patients who had LSS at 1, 3 and 5 years were 50.1% ± 0.7%, 59.2% ± 2.3% and 61.7% ± 2.7%. Multiple logistic regression analysis identified two variables as a risk factor for LSE; persistent endoleak (Odds ratio 9.56 (4.84-19.49), P <0.001) and low platelet count (Odds ratio 0.92 (0.86-0.99), P = 0.0224). The leading cause of endoleak in patients with LSE was type II. CONCLUSIONS: The incidence of LSE is not negligible over 5 year period. Patients with persistent endoleak and/or low platelet count should carefully be observed for LSE. CLINICAL TRIAL REGISTRATION: UMIN-CTR (UMIN000008345).
BACKGROUND: Sac behavior after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) is considered as a surrogate for the risk of late rupture. The purpose of the study is to assess the sac behavior of AAAs after EVAR. METHODS AND RESULTS: Late sac enlargement (LSE) (≥5 mm) and late sac shrinkage (LSS) (≥5 mm) were analyzed in 589 consecutive patients who were registered at 14 national centers in Japan. The proportions of patients who had LSE at 1, 3 and 5 years were 2.6% ± 0.7%, 10.0% ± 1.6% and 19.0% ± 2.9%. The proportions of patients who had LSS at 1, 3 and 5 years were 50.1% ± 0.7%, 59.2% ± 2.3% and 61.7% ± 2.7%. Multiple logistic regression analysis identified two variables as a risk factor for LSE; persistent endoleak (Odds ratio 9.56 (4.84-19.49), P <0.001) and low platelet count (Odds ratio 0.92 (0.86-0.99), P = 0.0224). The leading cause of endoleak in patients with LSE was type II. CONCLUSIONS: The incidence of LSE is not negligible over 5 year period. Patients with persistent endoleak and/or low platelet count should carefully be observed for LSE. CLINICAL TRIAL REGISTRATION: UMIN-CTR (UMIN000008345).
Authors: J Görich; N Rilinger; R Sokiranski; S Krämer; A Schütz; L Sunder-Plassmann; R Pamler Journal: J Endovasc Ther Date: 2000-08 Impact factor: 3.487
Authors: David C Brewster; John E Jones; Thomas K Chung; Glenn M Lamuraglia; Christopher J Kwolek; Michael T Watkins; Thomas M Hodgman; Richard P Cambria Journal: Ann Surg Date: 2006-09 Impact factor: 12.969
Authors: Jan D Blankensteijn; Sjors E C A de Jong; Monique Prinssen; Arie C van der Ham; Jaap Buth; Steven M M van Sterkenburg; Hence J M Verhagen; Erik Buskens; Diederick E Grobbee Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Andres Schanzer; Roy K Greenberg; Nathanael Hevelone; William P Robinson; Mohammad H Eslami; Robert J Goldberg; Louis Messina Journal: Circulation Date: 2011-04-10 Impact factor: 29.690
Authors: Eric Steinmetz; Brian G Rubin; Luis A Sanchez; Eric T Choi; Patrick J Geraghty; Jack Baty; Robert W Thompson; M Wayne Flye; David M Hovsepian; Daniel Picus; Gregorio A Sicard Journal: J Vasc Surg Date: 2004-02 Impact factor: 4.268